Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
The firms intend to seek CE marking and US Food and Drug Administration clearance for the test.
The medium has been cleared for transporting samples potentially containing flu A and tuberculosis.
Through its large network of ambulatory labs, the university's pathology and lab medicine department is evaluating a BioFire rapid diagnostic test for the flu.
On a conference call following the release of the earnings, the firm's CEO guided for lower 2018 ePlex placements than had been expected by analysts.
The firm plans to release a research-use-only version of its test by the end of the year, and is still hoping for FDA clearance in 2019.
Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.
The molecular test can provide results in 30 minutes from nasal swabs on a palm-sized instrument.
Synthetic Genomics is working on speeding up flu vaccine production, according to the San Diego Union-Tribune.
In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.